MindBio Therapeutics (XCNQ:MBIO) Interest Expense : C$-0.39 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. MindBio Therapeutics's interest expense for the three months ended in Mar. 2024 was C$ -0.05 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.39 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. MindBio Therapeutics's Operating Income for the three months ended in Mar. 2024 was C$ 0.15 Mil. MindBio Therapeutics's Interest Expense for the three months ended in Mar. 2024 was C$ -0.05 Mil. MindBio Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 was 3.08. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MindBio Therapeutics Interest Expense Historical Data

The historical data trend for MindBio Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Interest Expense Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Interest Expense

-0.16

-0.40

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial					-0.06	-0.22	-0.05	-0.07	-0.05

MindBio Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.39 Mil.

MindBio Therapeutics (XCNQ:MBIO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MindBio Therapeutics's Interest Expense for the three months ended in Mar. 2024 was C$-0.05 Mil. Its Operating Income for the three months ended in Mar. 2024 was C$0.15 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was C$3.55 Mil.

MindBio Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	0.154	/	-0.05
	=	3.08

The higher the ratio, the stronger the company's financial strength is.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.